Latest news with #Buckaroo
News.com.au
07-05-2025
- Sport
- News.com.au
‘It's someone else's turn': Ozzie Kheir out to deny Annabel Neasham fifth straight Hollindale Stakes success with Buckaroo
Buckaroo's part-owner Ozzie Kheir is confident that Annabel Archibald 's remarkable winning streak in the Hollindale Stakes will be halted on Saturday as he joked that the $500,000 Group 2 race should be named after the high-profile Sydney trainer. The newly married Archibald has won the past four editions of the 1800m race and will be vying for a fifth on the Gold Coast this week in partnership with her co-trainer and husband Rob. The Chris Waller -trained gelding Buckaroo is the clear favourite for the Hollindale Stakes at $3.80 with bookmakers, ahead of stablemate Lindermann ($5). The Archibald-trained Fawkner Park, Queensland star Antino and Eliyass, from the Gai Waterhouse and Adrian Bott stable, are next on the line at $7.50. 'I think it's someone else's turn to win the Hollindale, for sure,' Kheir said about ending Archibald's reign. 'We've got to stop that or else they'll call it the Archibald Cup soon. If you win it four times in a row, surely there has to be a discussion to name the race after you.' Last year's Melbourne Cup favourite, six-year-old Buckaroo had a highly successful spring campaign when he won the Group 1 Underwood Stakes (1800m) at Caulfield, the Group 2 Chelmsford Stakes (1600m) at Randwick and finished runner-up in majors the Turnbull Stakes (2000m) at Flemington and the Caulfield Cup (2400m). Buckaroo is coming off a light autumn campaign that included a ninth place in the $1m George Ryder Stakes at Rosehill in March and then he finished seventh out of 13 runners in the $5m Queen Elizabeth Stakes at Randwick on April 12. 'I thought his runs in both races were creditable, even though the form doesn't look good on paper. He sort of blew out a little bit in the Queen Elizabeth,' Kheir said. 'He loomed up very well and probably punctured the last 200m.' Kheir said Buckaroo would be 'cherry-ripe' for the Hollindale Stakes, where he will jump from barrier 12, and then go into the Group 1 $1m Doomben Cup (2000m) on May 24. 'All the reports are that he's going well at home and I think he'll run a good race (on Saturday),' he said. 'Although he's won on good ground, tracks with a bit of give are ideal for him. If we can get a Soft 5 or 6, that'll be to his liking.' Meanwhile, Kheir said Melbourne Cup runner-up Soulcombe was only a '40 per cent chance' of returning to the racetrack and wouldn't be back until next autumn at the earliest. The six-year-old gelding hasn't competed since finishing second to Without A Fight in the race that stops a nation in 2023 due to a series of setbacks, the latest being a tendon injury. Asked whether the star stayer would be retired, Kheir said: 'No, not yet. We haven't decided. 'We're going to put him through a rehab program over the next eight weeks and then assess how he recovers from that. 'It's definitely not great. I couldn't see him racing before the next autumn at the earliest. 'I would say he's a 40 per cent chance of being able to return to racing. 'He's probably one of the most talented horses we've owned. He's up there with one of our favourites. 'He's one horse that deserved to be a Group 1 winner and got awfully close but he was unlucky on the day.'
The Guardian
22-04-2025
- Entertainment
- The Guardian
‘I still don't know what it's about!' Buckaroo Banzai, the surreal 80s flop that became a cult classic
There are several surefire ways to reveal someone's character. Do they like pineapple on pizza? Do they think it's acceptable to talk in the cinema? And finally, how do they feel about the 1984 cult classic The Adventures of Buckaroo Banzai Across the 8th Dimension? This misshapen, esoteric and utterly magical science-fiction romp made less of a splash on release than it should have, but since then it has become a kind of celluloid speakeasy; a real 'if you know, you know' kind of movie. It all revolves around one man: Buckaroo Banzai, played by Peter Weller. 'For the life of me, I gotta tell you, Paul … I got no idea what the film is about to this day,' Weller says, on Zoom from Los Angeles. 'I know it's about a polymath guy, a brain surgeon, a gunslinger … but I still don't know what it's about! Kevin Smith once called it 'a genre-defying one-off'. He said, it's not action, it's not science fiction, it's not comedy: it's all those things. It's about race, it's about social science, it's about politics, existence, existentialism … Jeez, man! All I knew was that I dug the idea of playing a gun-slinging brain surgeon!' Buckaroo Banzai is all of those things and more. He's a renaissance man. The thinking man's action hero. As the film opens, we see him finishing up a gruelling, pioneering neurosurgical procedure alongside his colleague Dr Sidney 'New Jersey' Zweibel (Jeff Goldblum). Before long, he's downing tools to carry out an incredibly dangerous experiment in his jet car, which is fitted with an 'oscillation overthruster' (imagine the flux capacitor after a run-in with a garbage disposal). The world watches on as Buckaroo, equal parts Sherlock Holmes, James Bond and Adam Ant, burns towards a waiting mountain … and drives through it. From there, it gets even weirder, as Buckaroo and his friends battle a surreal interdimensional threat. But the real threat was from within: studio interference was rife during the film's legendarily fraught production process, resulting in an uneven, lumpy film – all part of its charm – made by bewilderingly talented people, on and off camera. 20th Century Fox even fired the renowned director of photography Jordan Cronenweth (the man who gave Blade Runner its unique look) halfway through the production. 'Jordan was a maestro, man,' says Weller, shaking his head. 'Like Rembrandt. It's not like our second DOP was a hack or anything, but Jordan was a one-off. You talk to Ridley [Scott], and he'll say, 'That guy was a painter.' Just look at the ambience of his scenes in the film, man. Look at the colour. Look at the softness.' But for every off-screen battle, there were cast members giving career-best performances to make up for it. And what a cast: Weller is best known for playing Alex Murphy in Robocop, but his warmth and wit as Buckaroo is a thing to behold. The character was a patchwork of Weller's personal heroes: 'I was a real aficionado of Adam Ant and Hendrix, and jazz guys. There were these amazing people who I rolled in there. Einstein. Elia Kazan.' John Lithgow's turn as the villainous Dr Emilio Lizardo is halfway between Mussolini and Gumby – a fervent, explosive maelstrom of idiocy. Goldblum is at his effortless best, wowing us long before Dr Ian Malcolm unbuttoned his shirt. Ellen Barkin's Penny Priddy is buttery and strange, and Christopher Lloyd's small but manic bad-guy performance sings. Sign up to Saved for Later Catch up on the fun stuff with Guardian Australia's culture and lifestyle rundown of pop culture, trends and tips after newsletter promotion But being released in cinemas at the same time as Ghostbusters, Raiders of the Lost Ark and Star Trek III: The Search for Spock meant that Buckaroo Banzai never stood a chance. Did the production woes, the screw-ups, the lay-offs, the box office, sour the memory of it all for Weller? He lights a cigar and mulls over the question. 'The way it's lasted, and the way people love it, is wonderful. Even when I didn't know what it was about,' he says. 'I was on a golf course with the wonderful Dennis Haysbert, who said, 'Peter, it's my favourite film.' I said, 'Why?' He says, 'Peter, it's about love.' And it is! It truly is. And that's what people love about it. It is about surrender, and happiness, and wondrous, wondrous science. And it brought me a lot of love from people who are friends to this day – I just had lunch with Goldblum in Florence, and a great time with Chris Lloyd in Japan. Lithgow, I haven't seen in a little while, but he's still a great pal.' In the years since the film came out, Weller has become, much like Buckaroo himself, a renaissance man. He acts, of course. But he also directs, is an accomplished musician (he and Goldblum performed together for years) and, in a very literal turn, now has a PhD in Italian renaissance art history. We talk about renaissance art for a full half hour, Weller flourishing his cigar as he takes me through a thrilling, byzantine travelogue of times past. We might not need a Buckaroo Banzai sequel – not when Weller embodies the spirit of Buckaroo so fully himself. Buckaroo Banzai is available to stream on Amazon Prime. Peter Weller's new book, Leon Battista Alberti in Exile: Tracing the Path to the First Modern Book on Painting, comes out 1 May
Yahoo
30-01-2025
- Health
- Yahoo
Meet the Faces of Zen: Elanco's Zenrelia(TM) (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal
Hunter, Trooper, Scrappy and Buckaroo find zen by using Zenrelia Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes between Zenrelia and Apoquel® (oclacitinib tablet) GREENFIELD, IN / / January 30, 2025 / Scratching, rubbing, chewing, licking. All signs of an irritated, itchy dog. With approximately 17 million U.S. dogs suffering from allergic skin disease, including atopic dermatitis, food allergies or flea sensitivity,1,2 these are the sounds too many pet parents and veterinarians hear. Today, Elanco Animal Health Incorporated (NYSE:ELAN), is introducing some of the first allergic dogs who have found zen and gotten back to normal by using Zenrelia. Zenrelia, which was approved by the U.S. Food and Drug Administration (FDA) and launched in September 2024, is a highly effective, convenient and safe once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. "Our research shows that when pet owners see their dog at their worst levels of itch, they're concerned, stressed, frustrated and anxious,3" said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. "Pet owners shouldn't allow allergic itch to disrupt zen for them or their pups. Zenrelia is designed to begin working from the very first dose4 and help get dogs back to normal."5 In fact, a newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, described the findings of a randomized, clinical trial which compared Zenrelia to the leading JAK inhibitor, Apoquel, in over 300 allergic dogs. The full study findings can be found at: The Zenrelia label includes a boxed warning related to concurrent vaccine administration based on the results of a vaccine response study. It's important for veterinarians to read the entire package insert, including the Boxed Warning, before prescribing Zenrelia. Meet Some of the Faces of Zen According to a survey of pet owners, itchy dog owners are eager to get back to a normal life with their dogs, with 82% agreeing they dream of the day their itchy dog becomes normal again and they understand that effective treatment is part of that solution.2 With Zenrelia now widely available, Zenrelia has expanded beyond the clinical trial to helping dogs across the country-and their pet owners-find zen. These real-world results give hope to millions of pet parents whose pets suffer from itch. Hunter from Ohio, found his zen with Zenrelia. This eight-year-old Chocolate lab suffered with dermatitis most of his life and as he got older, his symptoms-especially licking at his feet and lower legs got worse. His pet parent, Cristy, a receptionist at a vet clinic, tried everything her veterinarian had recommended to bring Hunter relief. Hunter had an extensive regimen of injections every 3-4 weeks, medicated shampoos and wipes, antihistamines, and during parts of the year when he was worse, he was on steroids. Even with this intensive routine his symptoms were never fully controlled. -until Hunter took Zenrelia. "His back feet were pretty much naked up until his first joint and his front feet would be scabby and scaly from the constant licking," Cristy said. "It was really discouraging as his dog mom that I couldn't do anything to help him. He's so much more comfortable since being on Zenrelia. It's such a relief that he has relief." According to Cristy, "It's worth talking to your veterinarian to see if it's something that your dog would benefit from." Individual results may vary and dogs should be up to date on vaccinations prior to starting Zenrelia. Trooper, a four-year-old Yorkshire Terrier, from Arizona, first got back to normal levels of itch when he participated in the Zenrelia clinical trial. When the trial concluded, the itch returned. His owner, Robin, was excited to get him back on the treatment now that Zenrelia is widely available. "Allergies are something he's going to have to suffer with his whole life," said Trooper's pet parent, Robin. "Having a solution for his allergies is such a relief. It makes my heart happy that I will be able to afford it and give him the relief he deserves." Lisa, pet mom to 9-year-old Yorkshire Terrier-Chihuahua mix Scrappy said she "tried everything under the sun" to help bring Scrappy relief. Scrappy's itching reached the point he lost a significant amount of fur, he didn't want to play or go on walks and no one was getting a good night's rest. Lisa tried numerous treatment options and felt depleted knowing his itch was never fully controlled, until she tried Zenrelia. After two days on Zenrelia, his itch level improved and after eight weeks on Zenrelia, Lisa is happy and relieved to see Scrappy back to a normal dog. According to Lisa, his hair has re-grown, he's taking long walks and he's a happy boy. "I was excited to get Trooper, Scrappy and some other patients started on Zenrelia as soon as it was available to order," said Dr. Tom Lewis, veterinarian and founder of Dermatology for Animals, a group of veterinary dermatology clinics committed to caring for pets with allergies. "Seeing these dogs get back to normal levels of itch and seeing the bond restored between the dog and pet parents is incredibly rewarding. Pet owners should contact their veterinarian and ask if Zenrelia is right for their dog." Buckaroo, an eight-year-old mixed breed from Texas, tried numerous treatment options without relief, including steroids and immunotherapy - until his veterinarian recommended Zenrelia. The photos below show Buckaroo's skin before Zenrelia, after three weeks of treatment, and after eight weeks of treatment. His owner noted, "he's now the happiest boy in the world and his energy levels have increased dramatically." "I've had the opportunity to use Zenrelia in my practice and it's helped several of my patients get back to normal levels of itch," said Dr. Brittany Lancellotti, a veterinary dermatologist at Veterinary Skin and Ear in Los Angeles, California. "In the fight against allergic dermatitis, I've found that every dog is different - it's great to have another effective treatment option in my toolbox." "I work with dermatologists around the country through the American College of Veterinary Dermatology," said Dr. Andrew Rosenberg, dermatologist, and director of medical operations at Animal Dermatology Clinic in New York and President of the American College of Veterinary Dermatology (ACVD). "It'S great to have another tool in the toolbox especially for both new and severe cases." Veterinarians in the U.S. can learn more and place orders for Zenrelia now at ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars - all to advance the health of animals, people, the planet and our enterprise. Learn more at INDICATIONS Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age. IMPORTANT SAFETY INFORMATION See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Dogs should not take Zenrelia for a time period before and after vaccination. Discuss your dog's vaccine schedule with your veterinarian. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs. Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Apoquel is a trademark of Zoetis Services, LLC. © 2025 Elanco or its affiliates. 1. AVMA Pet Ownership and Demographic Sourcebook 2022.2. Elanco Animal Health. Data on File.3. Elanco and FleishmanHillard TRUE Global Intelligence Survey.4. Elanco Animal Health. Data on File.5. Elanco Animal Health. Data on File. Media Contact Season Solorio +1.765.316.0233 Investor Contact Tiffany Kanaga +1.765.740.0314 Buckaroo before Zenrelia (left); Buckaroo after Zenrelia treatment (middle and right) View additional multimedia and more ESG storytelling from Elanco on Contact Info:Spokesperson: ElancoWebsite: info@ SOURCE: Elanco View the original press release on ACCESS Newswire Sign in to access your portfolio
